QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01670994 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Patient population did not benefit from single agent treatment.

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: ALT-801

Sponsor

Altor BioScience

Collaborators

[object Object]